Hakutulokset - Marc‐Eric Halatsch

Tarkenna hakua
  1. 1
    CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide

    CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous... Tekijä Richard E. Kast, Georg Karpel‐Massler, Marc‐Eric Halatsch

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?

    Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand? Tekijä Georg Karpel‐Massler, Ursula Schmidt, Andreas Unterberg, Marc‐Eric Halatsch

    Julkaistu 2009
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma

    Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma Tekijä Georg Karpel‐Massler, Chiaki Tsuge Ishida, Yiru Zhang, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Markus D. Siegelin

    Julkaistu 2017
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma

    BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma Tekijä Chiaki Tsuge Ishida, Elena Bianchetti, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Georg Karpel‐Massler, Markus D. Siegelin

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells

    Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells Tekijä Joachim Bischof, Mike‐Andrew Westhoff, Johanna Wagner, Marc‐Eric Halatsch, Stephanie Trentmann, Uwe Knippschild, Christian Rainer Wirtz, Timo Burster

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin

    Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin Tekijä Richard E. Kast, Quentin A. Hill, Didier Wion, Håkan Mellstedt, Daniele Focosi, Georg Karpel‐Massler, Tim Heiland, Marc‐Eric Halatsch

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners <i>in vitro</i> and <i>in vivo</i>

    TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners <i>in vitro</i> and <i>in vivo</i> Tekijä Georg Karpel‐Massler, Maïmouna Bâ, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis <i>in vitro</i> and <i>in vivo</i>

    Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis <i>in vitro</i> and <i>in vivo</i> Tekijä Georg Karpel‐Massler, Doruntina Ramani, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    RIST: A potent new combination therapy for glioblastoma

    RIST: A potent new combination therapy for glioblastoma Tekijä Lisa Nonnenmacher, Mike‐Andrew Westhoff, Simone Fulda, Georg Karpel‐Massler, Marc‐Eric Halatsch, Jens Engelke, Thomas Simmet, Selim Corbacioglu, Klaus‐Michael Debatin

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i>

    Inhibition of deubiquitinases primes glioblastoma cells to apoptosis <i>in vitro</i> and <i>in vivo</i> Tekijä Georg Karpel‐Massler, Matei A. Banu, Chang Shu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy

    A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy Tekijä Stephanie Ströbele, Matthias Schneider, Lukas Schneele, Markus D. Siegelin, Lisa Nonnenmacher, Shaoxia Zhou, Georg Karpel-Massle, Mike‐Andrew Westhoff, Marc‐Eric Halatsch, Klaus‐Michael Debatin

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells

    Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells Tekijä Georg Karpel‐Massler, Mike‐Andrew Westhoff, Shaoxia Zhou, Lisa Nonnenmacher, Annika Dwucet, Richard E. Kast, Max G. Bachem, Christian Rainer Wirtz, Klaus‐Michael Debatin, Marc‐Eric Halatsch

    Julkaistu 2013
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    The effects of PI3K-mediated signalling on glioblastoma cell behaviour

    The effects of PI3K-mediated signalling on glioblastoma cell behaviour Tekijä Julia Langhans, Lukas Schneele, Nancy Trenkler, Hélène von Bandemer, Lisa Nonnenmacher, Georg Karpel‐Massler, Markus D. Siegelin, Shaoxia Zhou, Marc‐Eric Halatsch, Klaus‐Michael Debatin, Mike‐Andrew Westhoff

    Julkaistu 2017
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma

    Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma Tekijä Maximilian Pruss, Annika Dwucet, Mine Tanriover, Michal Hlaváč, Richard E. Kast, Klaus‐Michael Debatin, Christian Rainer Wirtz, Marc‐Eric Halatsch, Markus D. Siegelin, Mike‐Andrew Westhoff, Georg Karpel‐Massler

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i>

    Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i> Tekijä Georg Karpel‐Massler, Chang Shu, Lily Chau, Matei A. Banu, Marc‐Eric Halatsch, Mike‐Andrew Westhoff, Yulian P. Ramirez, Alonzo H. Ross, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro

    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro Tekijä Qiyu Cao, Annika Hajosch, Richard E. Kast, Christopher Loehmann, Michal Hlaváč, Pamela Fischer‐Posovszky, Hannah A. Strobel, Mike‐Andrew Westhoff, Markus D. Siegelin, Christian Rainer Wirtz, Marc‐Eric Halatsch, Georg Karpel‐Massler

    Julkaistu 2024
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    A paired comparison between glioblastoma “stem cells” and differentiated cells

    A paired comparison between glioblastoma “stem cells” and differentiated cells Tekijä Matthias Schneider, Stephanie Ströbele, Lisa Nonnenmacher, Markus D. Siegelin, Melanie Tepper, Sebastien Stroh, Sebastian Hasslacher, Stefanie Enzenmüller, Gudrun Strauß, Bernd Baumann, Georg Karpel‐Massler, Mike‐Andrew Westhoff, Klaus‐Michael Debatin, Marc‐Eric Halatsch

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma

    Inhibition of NF-κB Signaling Ablates the Invasive Phenotype of Glioblastoma Tekijä Mike‐Andrew Westhoff, Shaoxia Zhou, Lisa Nonnenmacher, Georg Karpel‐Massler, Claudia Jennewein, Matthias Schneider, Marc‐Eric Halatsch, Neil O. Carragher, Bernd Baumann, Alexander Krause, Thomas Simmet, Max G. Bachem, Christian Rainer Wirtz, Klaus‐Michael Debatin

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    Phosphoinositide 3-Kinases Upregulate System x<sub>c</sub><sup>−</sup> <i>via</i> Eukaryotic Initiation Factor 2α and Activating Transcription Factor 4 – A Pathway Active in Glioblastomas and Epilepsy

    Phosphoinositide 3-Kinases Upregulate System x<sub>c</sub><sup>−</sup> <i>via</i> Eukaryotic Initiation Factor 2α and Activating Transcription Factor 4 – A Pathway Active in Gliobl... Tekijä Jan Lewerenz, Paul Baxter, Rebecca Kassubek, Philipp Albrecht, Joeri Van Liefferinge, Mike‐Andrew Westhoff, Marc‐Eric Halatsch, Georg Karpel‐Massler, Paul J. Meakin, John D. Hayes, Eleonora Aronica, Ilse Smolders, Albert C. Ludolph, Axel Methner, Marcus Conrad, Ann Massie, Giles E. Hardingham, Pamela Maher

    Julkaistu 2013
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3

    A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 Tekijä Marc‐Eric Halatsch, Richard E. Kast, Georg Karpel‐Massler, Benjamin Mayer, Oliver Zolk, Bernd Schmitz, Angelika Scheuerle, Ludwig Maier, Lars Bullinger, Regine Mayer‐Steinacker, Carl J. Schmidt, Katharina Zeiler, Ziad Elshaer, Patricia Panther, Birgit Schmelzle, Anke Hallmen, Annika Dwucet, Markus D. Siegelin, Mike‐Andrew Westhoff, Kristine Beckers, Gauthier Bouche, Tim Heiland

    Julkaistu 2021
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: